Survivin和Aurora-b在喉癌组织中的表达及其临床意义

胡慈浩, 王文华, 王全, 等. Survivin和Aurora-b在喉癌组织中的表达及其临床意义[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(10): 737-743. doi: 10.13201/j.issn.1001-1781.2017.10.001
引用本文: 胡慈浩, 王文华, 王全, 等. Survivin和Aurora-b在喉癌组织中的表达及其临床意义[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(10): 737-743. doi: 10.13201/j.issn.1001-1781.2017.10.001
HU Cihao, WANG Wenhua, WANG Quan, et al. The effects and expression of Survivin and Aurora-b in laryngeal carcinoma[J]. J Clin Otorhinolaryngol Head Neck Surg, 2017, 31(10): 737-743. doi: 10.13201/j.issn.1001-1781.2017.10.001
Citation: HU Cihao, WANG Wenhua, WANG Quan, et al. The effects and expression of Survivin and Aurora-b in laryngeal carcinoma[J]. J Clin Otorhinolaryngol Head Neck Surg, 2017, 31(10): 737-743. doi: 10.13201/j.issn.1001-1781.2017.10.001

Survivin和Aurora-b在喉癌组织中的表达及其临床意义

  • 基金项目:

    人口健康安全技术开发与应用研究(No:2016012706-4)

详细信息
    通讯作者: 何晓松,E-mail:hexiaosonggx@sina.com
  • 中图分类号: R739.6

The effects and expression of Survivin and Aurora-b in laryngeal carcinoma

More Information
  • 目的: 探讨Survivin和Aurora-b在喉癌组织中表达的意义及与其临床病理特征间的联系。探讨Survivin和Aurora-b的表达水平是否具有喉癌生物学标志物的研究价值,以及能否作为喉癌术后预测总生存率的预后指标。方法: 收集经病理科确诊的喉癌组织标本86例,同时选取癌旁组织86例和正常组织22例作为对照。采用免疫组织化学法检测Survivin 和Aurora-b在喉癌和癌旁及正常组织中的表达情况。结果: Survivin和Aurora-b在喉癌组织中的阳性表达率明显高于癌旁及正常组织,其差异有统计学意义(P<0.01)。Survivin蛋白的表达与淋巴结转移、复发情况等临床病理特征有相关性(P<0.05),而与年龄、性别、临床分期及分化情况等病理特征无相关性。Aurora-b的表达与临床分期、复发情况等临床病理特征有相关性(P<0.05),但与年龄、性别、分化情况及淋巴结转移等病理特征无相关性。生存曲线显示阴性组生存期都比阳性组高,提示Survivin和Aurora-b在喉癌中表达水平具有提示预后的意义,且均为负性预后因子。COX回归分析结果显示, 喉癌患者术后Aurora-b表达和复发情况为影响预后的独立危险因素(P<0.05);而Survivin表达和淋巴结转移情况则不是影响预后的独立危险因素。结论: 本研究表明Survivin和Aurora-b以及两者的协同作用可能在喉癌的发生、发展、转移和预后等方面扮演重要角色,其表达水平与肿瘤的恶性程度和侵袭性正相关,可能是预后不良的提示指征,在诊疗过程中具有预测预后的潜在研究价值。
  • 加载中
  • [1]

    KAMANGAR F, DORES G M, ANDERSON W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world [J]. J Clin Oncol,2006, 24:2137-2150.

    [2]

    HUANG Z G. The status and prospects of the basic research in larynx carcinoma[J]. Chin Arch Otol Head Neck Surg,2010, 14:57-57.

    [3]

    DE MIGUEL-LUKEN M J, CHAVES-CONDE M, DE MIGUEL-LUKEN V, et al. MAP17(PDZKIP1) as a novel prognostic biomarker for laryngeal cancer Oncotarget[J]. Oncotarget, 2015, 6:12625-12636.

    [4]

    CELENK F, BAYRAMOGLU I, YILMAZ A,et al. Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma[J]. J Craniofac Surg,2013,24:1114-1114.

    [5]

    LIONELLO M, LOVATO A, STAFFIERI A, et al. The EGFR-mTOR pathway and laryngeal cancer angiogenesis[J]. Eur Arch Otorhinolaryngol,2014, 271:757-764.

    [6]

    VAUGHT C, WEINBERGER P, SEYBT T P, et al. Prognostic implications of Survivin expression in squamous cell carcinoma of the larynx[J]. Laryngoscope,2010, 120:188-188.

    [7]

    ZHANG H, ZHANG D, LUAN X. Inhibition of the signal transducers and activators of transcription(STAT)3 signalling pathway by AG490 in laryngeal carcinoma cells[J]. J Int Med Res,2010, 38:1673-1681.

    [8]

    CHEVALIER D, LACCOURREYE O, BRASNU D, et al. Crycohyoidoepiglottopexy for glottic carcinoma with fixation o impaired motion of the true vocal cord: 5-year oncology results with 112 patients[J].Ann Otol Rhinol Laryngol,1997,106:364-369.

    [9]

    夏荣耀,张冉冉,孙亚娇,等.Survivin基因与肿瘤相关研究进展[J].现代肿瘤医学,2013, 21(3): 662-665.

    [10]

    HIMANI G, PRERNA S, GUPTA J C, et al. Survivin: a unique target for tumor therapy[J]. Cancer Cell Int, 2016, 16: 49-49.

    [11]

    SHEN Z, REN Y,YE D, et al. Significance and relationship between DJ-1 gene and survivin gene expression in laryngealsquamous cell carcinoma[J]. Eur J Histochem,2011, 55:9-9.

    [12]

    王菊香,杨宝良,裴士庚,等.Survivin与P53及ki67蛋白在喉癌组织中的表达及相关性[J].临床耳鼻喉头颈外科杂志,2015, 29(17):1545-1548.

    [13]

    CARMENA M, EARNSHAW W C. The cellular geography of aurora kinases[J]. Nat Rev Mol Cell Biol,2003,4:842-854.

    [14]

    QI G, YASUSEI K, TOSHINORI A, et al. Nuclear Aurora B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer[J].Oncol Lett,2012,3:1109-1114.

    [15]

    ALEXANDER H, ANJA P, FABIENNE V K, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck[J]. Oncotarget,2011, 2: 599-609.

    [16]

    ALEJANDRA G L, GONZALO F M, MARIANNA T, et al. Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development[J]. Mol Cell Biol, 2015, 35:3566-3578.

    [17]

    RANEE M,SEREBRIISKII I G, BARBARA B, et al. The role and targeting of Aurora kinases in head and neck cancer[J]. Lancet Oncol,2013, 14: e425-e435.

    [18]

    ZAYTSEV A V, DARIO S P, MAXIM G, et al. Bistability of a coupled Aurora B kinase-phosphatase system in cell division [J]. Life, 2016, 5: e10644-e10644.

    [19]

    LI S, DENG Z X, FU J Y, et al. Spatial Compartmentalization Specializes the Function of Aurora A and Aurora B[J]. J Biol Chem, 2015, 290: 17546-17558.

    [20]

    CARMENA M, WHEELOCK M, FUNABIKI H, et al. The chromosomal passenger complex(CPC): from easy rider to the godfather of mitosis[J]. Nature Rev Molecular Cell Biol,2012, 13: 789-803.

    [21]

    LENS S M, VADER G, MEDEMA R H. The case for Survivin as mitotic regulator[J].Curr Opin Cell Biol, 2006, 18:616-622.

    [22]

    张旭辉,于晓妉.染色体乘客复合体对细胞有丝分裂的调控作用[J].生命科学,2007,19(2):149-153.

    [23]

    苑中甫,武继琳.卵巢上皮性癌组织中Aurora-b和Survivin的表达[J].郑州大学学报,2011,46(4):577-580.

    [24]

    TEMME A, RIEBER E P, SCHMITZ M, et al. Increased p21(ras) activity in human fibroblasts transduced with Survivin enhances cell proliferation[J]. Biochem Biophys Res Commun,2005,327:765-773.

    [25]

    QI G, KUDO Y, ANDO T, et al. Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B[J]. Oral Oncology,2010, 46: 263-270.

    [26]

    董丹丹,肖燕燕,刘伟,等.Aurora-B激酶及其抑制剂研究进展[J].药学学报,2013,48(4):457-465.

  • 加载中
计量
  • 文章访问数:  106
  • PDF下载数:  222
  • 施引文献:  0
出版历程
收稿日期:  2017-02-23

目录